Drugs /

peripheral blood stem cell transplantation

Back to Drugs List

Overview

NCI Definition [1]:
A method of hematopoietic reconstitution utilizing stem cells harvested from the circulating blood of a patient or donor. Peripheral blood stem cell transplantation (PBSCT) is used for the treatment of certain blood disorders, following partial or complete bone marrow ablation, or following high dose chemotherapy or radiation treatment for cancer. Immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells. Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).

Clinical Trials

View Clinical Trials for peripheral blood stem cell transplantation

Peripheral blood stem cell transplantation has been investigated in 20 clinical trials, of which 12 are open and 8 are closed. Of the trials investigating peripheral blood stem cell transplantation, 5 are phase 1 (2 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open).

Complex karyotype, Hypodiploidy, and IGH-FGFR3 Fusion are the most frequent biomarker inclusion criteria for peripheral blood stem cell transplantation clinical trials.

Acute lymphoblastic leukemia, acute myeloid leukemia, and multiple myeloma are the most common diseases being investigated in peripheral blood stem cell transplantation clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Peripheral Blood Stem Cell Transplantation
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Peripheral Blood Stem Cell Transplantation
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating peripheral blood stem cell transplantation and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

NCIT ID [1]:
C15430

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.